Keeping an Eye on 8 New Payment Trends

AUGUST 25, 2025

Transforming Access and Affordability Through Digital Solutions

AUGUST 24, 2025

Pharmacists Step Up To Monitor AI Algorithms

AUGUST 23, 2025

Email This Article

POSTED: APRIL 23, 2019

Magellan Program Boosts Uptake of Biosimilar Infliximab

When a comprehensive management approach—switching all patients to a biosimilar agent—was used, health plans saw a shift in biosimilar utilization of up to 86%, as well as a 34% cost savings.

A link to this article will be included in this email.

Recipient's Email Address:

Enter email addresses separated by commas if sending to more than one person. (200 characters max)

Your Name:

Your Email Address:

Send me a copy

Personal Message: (Optional)

These email addresses will only be used to send out this message.

Please wait..

Policy

APRIL 23, 2019

Magellan Program Boosts Uptake of Biosimilar Infliximab

To read the full story, Log in or Sign up for a Free Account

Check out our new Clinical tab!

We've added an exciting new feature to our website. Click on "Clinical" in the navbar to explore!

The following result is from the NPI Registry Public Search database. You can click on the NPI number to view detailed information and verify its accuracy. If your NPI is not found in this search, you can try searching again using the form below. If you have difficulty finding your NPI number please contact us at web@mcmahonmed.com

First Name

Last Name

Organization/Institution

State

NPI	Name	Organization/ Institution	State	Zip Code	Taxonomy	Credential	Select